Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

SELL
$2.29 - $4.08 $459,071 - $817,909
-200,468 Reduced 72.9%
74,532 $171,000
Q2 2022

Aug 12, 2022

BUY
$2.39 - $4.93 $151,765 - $313,055
63,500 Added 30.02%
275,000 $778,000
Q1 2022

May 16, 2022

BUY
$3.45 - $8.77 $332,925 - $846,305
96,500 Added 83.91%
211,500 $960,000
Q4 2021

Feb 14, 2022

BUY
$8.01 - $12.84 $921,150 - $1.48 Million
115,000 New
115,000 $934,000
Q4 2020

Feb 12, 2021

SELL
$15.87 - $31.64 $1.05 Million - $2.08 Million
-65,855 Closed
0 $0
Q3 2020

Nov 12, 2020

SELL
$15.7 - $20.84 $1.48 Million - $1.96 Million
-94,145 Reduced 58.84%
65,855 $1.22 Million
Q2 2020

Aug 12, 2020

SELL
$8.21 - $21.02 $205,250 - $525,500
-25,000 Reduced 13.51%
160,000 $2.85 Million
Q1 2020

May 14, 2020

BUY
$7.81 - $18.82 $429,550 - $1.04 Million
55,000 Added 42.31%
185,000 $1.7 Million
Q4 2019

Feb 12, 2020

SELL
$9.73 - $19.31 $389,200 - $772,400
-40,000 Reduced 23.53%
130,000 $2.23 Million
Q3 2019

Nov 13, 2019

BUY
$10.15 - $16.89 $862,750 - $1.44 Million
85,000 Added 100.0%
170,000 $1.77 Million
Q2 2019

Aug 14, 2019

SELL
$14.6 - $20.6 $146,000 - $206,000
-10,000 Reduced 10.53%
85,000 $1.33 Million
Q1 2019

May 15, 2019

BUY
$15.53 - $19.75 $77,650 - $98,750
5,000 Added 5.56%
95,000 $1.74 Million
Q4 2018

Feb 13, 2019

BUY
$15.58 - $28.41 $817,950 - $1.49 Million
52,500 Added 140.0%
90,000 $1.5 Million
Q3 2018

Nov 14, 2018

BUY
$25.99 - $30.6 $194,925 - $229,500
7,500 Added 25.0%
37,500 $1.06 Million
Q2 2018

Aug 13, 2018

BUY
$27.78 - $38.53 $833,400 - $1.16 Million
30,000 New
30,000 $849,000
Q1 2018

May 14, 2018

SELL
$27.78 - $35.19 $1.11 Million - $1.41 Million
-40,000 Closed
0 $0
Q4 2017

Feb 12, 2018

BUY
$23.33 - $35.01 $933,199 - $1.4 Million
40,000
40,000 $1.17 Million

Others Institutions Holding CLLS

About Cellectis S.A.


  • Ticker CLLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,510,800
  • Market Cap $71M
  • Description
  • Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...
More about CLLS
Track This Portfolio

Track Hudson Bay Capital Management LP Portfolio

Follow Hudson Bay Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hudson Bay Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Hudson Bay Capital Management LP with notifications on news.